MTAP deletion

News alerts, weekly reports and conference planners

Entrez ID:

4507

Related biomarkers:

‹

›

MTAP deletion	Gastric Cancer	MTAP deletion	Gastric Cancer	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2
MTAP deletion	Non Small Cell Lung Cancer	MTAP deletion	Non Small Cell Lung Cancer	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2
MTAP deletion	Urothelial Cancer	MTAP deletion	Urothelial Cancer	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP deletion	Squamous Cell Carcinoma of Head and Neck	MTAP deletion	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3
MTAP deletion	Gallbladder Cancer	MTAP deletion	Gallbladder Cancer	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
MTAP deletion	Neurofibrosarcoma	MTAP deletion	Neurofibrosarcoma	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
MTAP deletion	Mesothelioma	MTAP deletion	Mesothelioma	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
MTAP deletion	Non Small Cell Lung Cancer	MTAP deletion	Non Small Cell Lung Cancer	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
MTAP deletion	Melanoma	MTAP deletion	Melanoma	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3	MRTX1719 Sensitive: C3 – Early Trials MRTX1719 Sensitive : C3
MTAP deletion	Esophageal Cancer	MTAP deletion	Esophageal Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Head and Neck Cancer	MTAP deletion	Head and Neck Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Bladder Cancer	MTAP deletion	Bladder Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Colorectal Cancer	MTAP deletion	Colorectal Cancer	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	MRTX1719 Sensitive: D – Preclinical MRTX1719 Sensitive : D	MRTX1719 Sensitive: D – Preclinical MRTX1719 Sensitive : D
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Glioblastoma	MTAP deletion	Glioblastoma	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D

MTAP deletion

Associations